Results 281 to 290 of about 25,779 (305)

Postmarketing Surveillance for Oncology Drugs

Clinical Journal of Oncology Nursing, 2008
Adverse effects of cancer therapies may occur more than three decades after drug administration. Continued vigilance in postmarketing use of oncology agents is necessary to accurately track adverse effects, update prescribing information, and alert healthcare providers in a timely manner.
Susan Moore, Pamela Hallquist Viale
openaire   +3 more sources

Postmarketing Surveillance of the Safety of Cyclic Etidronate

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1998
To evaluate the safety of cyclic etidronate in routine clinical practice, we obtained information from 550 general practices in the United Kingdom that provide the medical records to the General Practice Research Database. A group of 7977 patients taking cyclic etidronate and two age‐, gender‐, and practice‐matched control groups, one with osteoporosis
Lucien Abenhaim, Cyrus Cooper, Hubert G. M. Leufkens, Tjeerd van Staa   +3 more
openaire   +4 more sources

Postmarketing Surveillance in Japan

Drug Information Journal, 1994
In April 1993, the Japanese Ministry of Health and Welfare (MHW) implemented an official guideline on good postmarketing surveillance (PMS) practice. This paper outlines the guideline, which calls for the establishment of a PMS department within each pharmaceutical company and enables the MHW to conduct inspections.
openaire   +2 more sources

MS treatment: Postmarketing studies

Journal of the Neurological Sciences, 2007
Multiple sclerosis (MS) is an inflammatory chronic demyelinating disease. Nowadays, there are several registered drugs aimed to control the disease activity. Because these drugs are given parenterally for years, it is of utmost importance to attain maximum adherence to treatment through close and permanent care of patients.
openaire   +3 more sources

Concerns with postmarketing surveillance

American Journal of Health-System Pharmacy, 1984
Michael J. Norvell, Robert J. Anderson
openaire   +3 more sources

Postmarketing Surveillance: Beyond medWatch

JAMA: The Journal of the American Medical Association, 1993
To the Editor. —As one who has actively participated in adverse effects surveillance over the past 10 years, 1,2 I wish to applaud the new Food and Drug Administration (FDA)MEDWATCHinitiative. 3 The FDA commissioner and his staff are to be congratulated on recognizing that major efforts must be made to heighten awareness of the importance of reporting
openaire   +3 more sources

Drug Postmarketing Studies

JAMA, 2013
Cathryn Lee, John Jenkins, Mwango Kashoki   +2 more
openaire   +3 more sources

Drug Postmarketing Studies—Reply

JAMA, 2013
Kevin M. Fain, G. Caleb Alexander
openaire   +3 more sources

Postmarketing Surveillance (PMS)

1985
The term postmarketing surveillance should convey the meaning that the use of a drug after marketing is surveyed both for efficacy and safety; however, as the term is currently used, the emphasis is on safety rather than efficacy. One of the reasons for the lack of emphasis on efficacy has been the fact that the originating pharmaceutical company will ...
openaire   +2 more sources

Postmarketing Drug Sureillance

Journal of Pharmaceutical Sciences, 1979
openaire   +3 more sources